Clinical Trial Update: MLN8237 to Treat Children With Relapsed/Refractory Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial update showing completion of MLN8237 (alisertib) in children with relapsed/refractory solid tumors, including neuroblastoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• MLN8237 (alisertib)

Snippet

Sponsor: Children's Oncology Group | Conditions: Unspecified Childhood Solid Tumor, Excluding CNS, Neuroblastoma | Phase 1 | Status: COMPLETED